Viatris to create ophthalmology franchise via two M&A deals

8 November 2022
viatris_large

Generics major Viatris (Nasdaq: VTRS) yesterday said it intends to create an ophthalmology franchise by acquiring two companies, Oyster Point Pharma (Nasdaq: OYST) and Famy Life Sciences.

The decision was welcomed by investors as the company’s shares leapt more than 13% to $10.97. Oyster Point did even better, with its shares leaping 38.6% to $11.57.

Together, the two acquisitions have an aggregate purchase price of around $700-$750 million, which Viatris expects to fund with cash on hand.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics